Surgical management considerations in cystic prolactinomas—a single center case series
- 13 Downloads
The optimal treatment of prolactinomas with a predominantly cystic component remains poorly defined. The cystic tumor component is considered to respond less favorably to medical treatment, thereby advocating surgical management. The purpose of this study was to assess remission rates in surgically treated cystic prolactinomas, and to compare outcomes to similarly treated solid micro- and macroprolactinomas.
Clinical and imaging data were retrospectively compiled from 56 patients who underwent transsphenoidal resection, for symptomatic prolactinomas, from 2004 to 2018, at a single academic institution. Pituitary adenomas were subdivided according to tumor size and tumor consistency: cystic prolactinomas (>50% cystic tumor component) n = 17; solid microprolactinomas (<10 mm) n = 10; and solid macroprolactinomas (≥10 mm) n = 29. Remission was defined as a prolactin level of <10 ng/dl either immediately postoperative or at a later time point.
Median tumor size was 15 mm for cystic prolactinomas, 7 mm for solid microprolactinomas, and 25.5 mm for solid macroprolactinomas. Remission was achieved in 76% (n = 13/17) of surgically treated cystic prolactinomas, 100% (n = 10/10) of solid microprolactinomas, and 24% (n = 7/29) of solid macroprolactinomas. More than 44% of solid macroprolactinomas had a Knosp grade > 3, while most cystic prolactinomas (93.8%) and all solid microprolactinomas (100%) had a Knosp grade ≤ 2.
Despite their large tumor size (≥10 mm), high remission rates can be expected with surgically treated cystic prolactinomas. This case series of cystic prolactinomas demonstrates the successful use of transsphenoidal surgery as a favorable, and a potentially curative alternative to dopaminergic therapy in this patient population.
KeywordsCystic prolactinoma Microprolactinoma Macroprolactinoma Transsphenoidal surgery Surgical remission
We thank Patrick William Hosokawa for the support in statistical analysis, Surgical Outcome and Applied Research, Department of Surgery, University of Colorado School of Medicine.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.F.F. Casanueva, M.E. Molitch, J.A. Schlechte, R. Abs, V. Bonert, M.D. Bronstein, T. Brue, P. Cappabianca, A. Colao, R. Fahlbusch, H. Fideleff, M. Hadani, P. Kelly, D. Kleinberg, E. Laws, J. Marek, M. Scanlon, L.G. Sobrinho, J.A. Wass, A. Giustina, Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin. Endocrinol. 65(2), 265–273 (2006). https://doi.org/10.1111/j.1365-2265.2006.02562.x CrossRefGoogle Scholar
- 4.S. Melmed, F.F. Casanueva, A.R. Hoffman, D.L. Kleinberg, V.M. Montori, J.A. Schlechte, J.A. Wass, S. Endocrine, Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96(2), 273–288 (2011). https://doi.org/10.1210/jc.2010-1692 CrossRefPubMedGoogle Scholar
- 6.World Medical Association, Declaration of Helsinki. Ethical principles for medical research involving human subjects. J. Indian Med. Assoc. 107(6), 403–405 (2009)Google Scholar
- 21.J. Kreutzer, R. Buslei, H. Wallaschofski, B. Hofmann, C. Nimsky, R. Fahlbusch, M. Buchfelder, Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur. J. Endocrinol. 158(1), 11–18 (2008). https://doi.org/10.1530/EJE-07-0248 CrossRefPubMedGoogle Scholar
- 26.P.R. Jethwa, T.D. Patel, A.F. Hajart, J.A. Eloy, W.T. Couldwell, J.K. Liu, Cost-Effectiveness Analysis of Microscopic and Endoscopic Transsphenoidal Surgery Versus Medical Therapy in the Management of Microprolactinoma in the United States. World Neurosurg. 87, 65–76 (2016). https://doi.org/10.1016/j.wneu.2015.10.090 CrossRefPubMedGoogle Scholar